Skip to main content
SpringerLink
Log in

Infliximab in Psoriasis and Psoriatic Arthritis

  • Clinical Management Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Psoriasis is a chronic inflammatory disorder of the skin and joints. Although rarely life threatening, psoriasis can significantly impair quality of life (QOL) and cause considerable physical and psychological distress. Between 6 and 42% of patients with psoriasis develop psoriatic arthritis, which is characterized by stiffness, pain, swelling and tenderness of the joints. Nail psoriasis is highly prevalent in both plaque-type psoriasis and psoriatic arthritis and is found in approximately 50% of patients with psoriasis and in 80% of patients with psoriatic arthritis. Infliximab, a chimeric human-murine monoclonal antibody directed against tumour necrosis factor α, is approved in the USA and EU for the treatment of plaque psoriasis and psoriatic arthritis at a recommended dosage of 5 mg/kg administered by intravenous infusion at 0,2 and 6 weeks, then every 8 weeks thereafter. The EXPRESS and EXPRESS II trials demonstrated that infliximab is efficacious as induction and maintenance therapy in the treatment of moderate to severe plaque psoriasis and also improved health-related QOL. Infliximab is also efficacious in the treatment of psoriatic arthritis, as shown in the IMPACT and IMPACT II studies. Infliximab is generally well tolerated, with a similar adverse event profile in both psoriasis and psoriatic arthritis. The use of infliximab in three case reports is presented. The patients are similar to those normally seen by clinicians, and include a male patient with plaque psoriasis and a history of severe psoriatic arthritis who was corticosteroid dependent and in whom other systemic treatments were not effective or were not able to be used. This patient showed a rapid response to infliximab with no skin lesions or arthritis after 7 weeks’ treatment. Infliximab was also safe and effective in the treatment of a female patient with plaque and nail psoriasis and a history of psoriatic arthritis. Importantly, this case report supports the efficacy of infliximab in psoriatic nail disease in the context of severe skin and joint involvement. Case 3 describes a young male patient with moderate plaque-type psoriasis associated with severe nail involvement and early signs of psoriatic arthritis. Treatment with infliximab improved nail psoriasis and appears to be an effective biological treatment for nail psoriasis. Importantly, ultrasound was able to diagnose joint involvement, as seen from the proliferative synovitis in the distal interphalangeal joint and mild enthesitis, despite there being no clinical evidence of psoriatic arthritis. This case report highlights the importance of early screening. If such abnormalities are detected early on in the course of psoriasis, clinicians may be able to predict which patients are more likely to develop psoriatic arthritis, and therefore offer effective and long-term treatment that may reduce the disability and impairment of daily activities that can be associated with psoriatic arthritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58(5): 826–50

    Article  PubMed  Google Scholar 

  2. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients’ beliefs and attitudes towards the disease. Br J Dermatol 1996; 135(4): 533–7

    Article  PubMed  CAS  Google Scholar 

  3. Augustin M, Kruger K, Radtke MA, et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216(4): 366–72

    Article  PubMed  CAS  Google Scholar 

  4. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 Suppl 2: ii14–17

    Google Scholar 

  5. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008; 58(5): 851–64

    Article  PubMed  Google Scholar 

  6. Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57(1): 1–27

    Article  PubMed  Google Scholar 

  7. Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis-clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 2004; 43(6): 790–4

    Article  CAS  Google Scholar 

  8. Lawry M. Biological therapy and nail psoriasis. Dermatol Ther 2007; 20(1): 60–7

    Article  PubMed  Google Scholar 

  9. Reich K, Ortonne JP, Kerkmann U, et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial. Dermatology 2010; 221(2): 172–8

    Article  PubMed  CAS  Google Scholar 

  10. Augustin M, Reich K, Blome C, et al. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 2010; 163(3): 580–5

    Article  PubMed  CAS  Google Scholar 

  11. Baran R. The burden of nail psoriasis: an introduction. Dermatology 2010; 221 Suppl 1:1–5

    Article  PubMed  Google Scholar 

  12. Langley RG, Dauden E. Treatment and management of psoriasis with nail involvement: a focus on biologic therapy. Dermatology 2010; 221 Suppl 1: 29–42

    Article  PubMed  Google Scholar 

  13. Papoutsaki M, Costanzo A. Diagnosis and treatment of psoriasis and psoriatic arthritis. BioDrugs 2012; Citation to be confirmed at publication

  14. Centocor Ortho Biotech Inc. Remicade(RM) (infliximab) for IV injection. [Online] 2009; Available from: http://www.remicade.com/remicade/assets/ HCP_PPI.pdf

  15. Electronic Medicines Compendium. Remicade 100mg powder for concentrate for solution for infusion. Summary of Product Characteristics. Schering- Plough Ltd. [Online] 2010; Available from: http://www.medicines.org.uk/emc/document.aspx?documentId=3236

  16. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366 (9494): 1367–74

    Article  PubMed  CAS  Google Scholar 

  17. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56(1): 31e1–15

    Article  Google Scholar 

  18. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo- controlled trial. J Am Acad Dermatol 2004; 51(4): 534–42

    Article  PubMed  Google Scholar 

  19. Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006; 154(6): 1161–8

    Article  PubMed  CAS  Google Scholar 

  20. Feldman SR, Gottlieb AB, Bala M, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate- to-severe psoriasis. Br J Dermatol 2008; 159(3): 704–10

    Article  PubMed  CAS  Google Scholar 

  21. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52(4): 1227–36

    Article  PubMed  CAS  Google Scholar 

  22. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64(8): 1150–7

    Article  PubMed  CAS  Google Scholar 

  23. Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008; 35(5): 869–76

    PubMed  CAS  Google Scholar 

  24. Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007; 66(4): 498–505

    Article  PubMed  CAS  Google Scholar 

  25. Woolacott N, Bravo Vergel Y, Hawkins N, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2006; 10(31): iii–iv, xiii-xvi, 1-239

    PubMed  CAS  Google Scholar 

  26. Tan AL, Rhodes LA, Marzo-Ortega H, et al. What imaging has told us about psoriatic arthritis. Rheumatology in Practice 2008; 5(4): 14–16

    Google Scholar 

  27. De Filippis LG, Caliri A, Lo Gullo R, et al. Ultrasonography in the early diagnosis of psoriasis-associated enthesopathy. Int J Tissue React 2005; 27(4): 159–62

    PubMed  Google Scholar 

  28. Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49(2): 206–12

    Article  PubMed  Google Scholar 

  29. Noiles K, Vender R. Nail psoriasis and biologics. J Cutan Med Surg 2009; 13(1): 1–5

    PubMed  Google Scholar 

  30. Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol 2009; 23 Suppl 1: 15–21

    Article  PubMed  Google Scholar 

  31. Bianchi L, Bergamin A, de Felice C, et al. Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol 2005; 52(4): 736–7

    Article  PubMed  Google Scholar 

  32. Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2011; DOI: 10.1136/ard.2011.150995

  33. Adisen E, Aral A, Aybay C, et al. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study. J Dermatol 2010; 37(8): 708–13

    Article  PubMed  CAS  Google Scholar 

  34. Roux CH, Brocq O, Breuil V, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007; 46(4): 695–8

    Article  CAS  Google Scholar 

  35. Puig L, Barco D, Alomar A. Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature. Dermatology 2010; 220(1): 71–6

    Article  PubMed  Google Scholar 

  36. Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216(2): 152–5

    Article  PubMed  CAS  Google Scholar 

  37. Saraceno R, Schipani C, Mazzotta A, et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008; 57(4): 290–5

    Article  PubMed  CAS  Google Scholar 

  38. Briot K, Gossec L, Kolta S, et al. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol 2008; 35(5): 855–61

    PubMed  CAS  Google Scholar 

  39. McGonagle D, Tan AL, Benjamin M. The nail as a musculoskeletal append- age-implications for an improved understanding of the link between psoriasis and arthritis. Dermatology 2009; 218(2): 97–102

    Article  PubMed  Google Scholar 

  40. Tan AL, Benjamin M, Toumi H, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis-a high-resolution MRI and histological study. Rheumatology (Ox- ford) 2007; 46(2): 253–6

    Article  CAS  Google Scholar 

  41. Wortsman X, Jemec GB. Ultrasound imaging of nails. Dermatol Clin 2006; 24(3): 323–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Third Department of Dermatology, ‘A. Syggros’ Hospital, Athens, Greece

    Marina Papoutsaki

  2. Department of Dermatology and Venereology, Centro Hospitalar de São João EPE, Porto, Portugal

    Filipa Osório

  3. Department of Dermatology and Venereology, Centro Hospitalar de São João EPE, Porto, Portugal

    Paulo Morais

  4. Department of Dermatology and Venereology, Faculty of Medicine, University of Porto, Porto, Portugal

    Paulo Morais

  5. Department of Dermatology, Hospital Santo António, Porto, Portugal

    Tiago Torres

  6. Department of Dermatology and Venereology, Centro Hospitalar de São João EPE, Porto, Portugal

    Sofia Magina

  7. Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal

    Sofia Magina

  8. Department of Dermatology, University of Rome Tor Vergata, Rome, Italy

    Sergio Chimenti & Antonio Costanzo

Authors
  1. Marina Papoutsaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Filipa Osório
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paulo Morais
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tiago Torres
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sofia Magina
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sergio Chimenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Antonio Costanzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marina Papoutsaki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Papoutsaki, M., Osório, F., Morais, P. et al. Infliximab in Psoriasis and Psoriatic Arthritis. BioDrugs 27 (Suppl 1), 13–23 (2013). https://doi.org/10.1007/BF03325638

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03325638

Keywords

Search

Navigation